{"id":828898,"date":"2025-03-24T08:16:35","date_gmt":"2025-03-24T12:16:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-financial-results\/"},"modified":"2025-03-24T08:16:35","modified_gmt":"2025-03-24T12:16:35","slug":"lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-financial-results\/","title":{"rendered":"Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase<\/i>\n <\/p>\n

\n Recognized EsoGuard revenue of $1.2 million<\/span> in 4Q24 \u00a0<\/i>\n <\/p>\n

\n New sales channel generated over 20 new cash-pay concierge medicine contracts<\/i>\n <\/p>\n

\n Secured first agreement to pay for EsoGuard under state biomarker legislation<\/i>\n <\/p>\n

\n Conference call and webcast to be held today, March 24<\/span>th<\/sup> at 8:30 AM EDT<\/span><\/i>\n <\/p>\n

\n
\n NEW YORK<\/span>
\n <\/span>, March 24, 2025<\/span><\/span> \/PRNewswire\/ — Lucid Diagnostics Inc.<\/a><\/u><\/b>\u00a0(Nasdaq: LUCD)\u00a0(“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)\u00a0(“PAVmed”), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024<\/span>.<\/p>\n

\n

\n
\n \"Lucid
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Conference Call and Webcast<\/b>\n <\/p>\n

The webcast will take place on Monday, March 24, 2024<\/span>, at 8:30 AM<\/span> and will be accessible in the investor relations section of the Company’s website at luciddx.com<\/a>.\u00a0 Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid Diagnostics Business Update” to join.<\/p>\n

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at luciddx.com<\/a><\/u>.<\/p>\n

\n Business Highlights<\/b>\n <\/p>\n

“The Lucid team finished 2024 on a strong note and 2025\u2014which promises to be a pivotal year\u2014is off to an exceptional start marked by significant advancements in EsoGuard’s commercial coverage, sales channels, and clinical evidence base,” said Lishan Aklog<\/span>, M.D.<\/a>, Lucid’s Chairman and Chief Executive Officer. “We believe we are on the cusp of achieving broader payor coverage for EsoGuard and expect our focus on new contractually-guaranteed revenue sales channels, including concierge medicine, to drive revenue growth in the second half of 2025. We are now well positioned to capitalize on EsoGuard’s very large clinical and market opportunity.”<\/p>\n